Start-up gains $30M in Series A funds

With human trials for an experimental Alzheimer's therapy looming, San Diego-based Sonexa Therapeutics has closed its first round of venture funds with $30 million in the bag. Domain Associates, Scale Venture Partners and Alta Partners led the round. Sonexa says that it licensed a development compound to most world markets from a Japanese company. According to the release, the Sonexa team includes president and CMO Sharon Rogers, Ph.D., "who played a leading role in developing Aricept, the top-selling Alzheimer's medication."

- check out the press release

ALSO: Check out the top 20 VC deals of 2007. Report

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.